Inflammatory and immune pathway targets

The term inflammatory and immune pathway targets refers to a broad and heterogeneous category of molecular entities rather than a single specific protein or receptor. These targets encompass a wide array of cytokines, chemokines, cell surface receptors, and intracellular signaling molecules that orchestrate the body's defense mechanisms and inflammatory responses (Source: NIH, National Institute of Allergy and Infectious Diseases). Key examples include Tumor Necrosis Factor (TNF), various Interleukins (IL-1, IL-6, IL-17), and Janus Kinases (JAK), all of which are critical for signal transduction in immune cells (Source: StatPearls, Inflammation). While these pathways are essential for host defense against pathogens and tissue repair, their chronic or dysregulated activation is a primary driver of autoimmune disorders, such as rheumatoid arthritis and inflammatory bowel disease, as well as chronic inflammatory conditions (Source: Nature Reviews Drug Discovery). Pharmacological intervention in these pathways aims to restore immune homeostasis by inhibiting specific mediators or signaling cascades. However, because these targets are integral to normal immune surveillance, therapeutic modulation often carries significant safety risks, most notably an increased susceptibility to serious infections and potential long-term risks of malignancy (Source: PubMed, PMC7151630).

Other names

Immune system targetsInflammatory mediatorsImmunomodulatory targetsInflammatory signaling molecules

Drugs targeting these pathways typically act by neutralizing pro-inflammatory cytokines, blocking cell-surface receptors, inhibiting intracellular signaling kinases (such as JAK or MAPK), or modulating the activity of transcription factors to reduce the production of inflammatory mediators.